drugset / Trial / NCT01508247

A Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months

NCT01508247 ↗

RandomizedParallel-groupTriple-blindPrevention

Summary

Since its discovery in 1969, enterovirus 71 (EV71) has been recognised as a frequent cause of epidemics of hand-foot-mouth disease (HFMD) associated with severe neurological sequelae in a small proportion of cases. There has been a significant increase in EV71 epidemic activity throughout the Asia-Pacific region since 1997. Recent HFMD epidemics in this region have heen associated with a severe from of brainstem encephalitis associated with pulmonary oedema and high case-fatality rates. The data from the phase 1 and 2 trials suggested that the inactivated EV71 vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese children and infants. According to the immunogenicity and safety results, the 320U with adjuvant with immunizing schedule of two doses (per 28 day) will be applied in phase 3 clinical trial.

Timeline

Start
2012-01
Primary completion
2013-03
Completion
2013-03

Outcome

Met primary endpoint

paper Vaccine efficacy was 90·0% (95% CI 67·1-96·9) against EV71-associated HFMD (p=0·0001) PMID 23726161 ↗

paper 80·4% (95% CI 58·2-90·8) against EV71-associated disease (p<0·0001). PMID 23726161 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject inactivated vaccine(vero cell) against EV71 Vaccine 320 iu —